221 related articles for article (PubMed ID: 34703037)
1. Glial Cells as Possible Targets of Neuroprotection through Neurotrophic and Antioxidative Molecules in the Central and Enteric Nervous Systems in Parkinson's Disease.
Isooka N; Miyazaki I; Asanuma M
Acta Med Okayama; 2021; 75(5):549-556. PubMed ID: 34703037
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic strategy for Parkinson's disease: targeting zinc-binding protein in astrocytes].
Miyazaki I; Asanuma M
Nihon Yakurigaku Zasshi; 2021; 156(2):76-80. PubMed ID: 33642534
[TBL] [Abstract][Full Text] [Related]
3. Neuron-Astrocyte Interactions in Parkinson's Disease.
Miyazaki I; Asanuma M
Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
[TBL] [Abstract][Full Text] [Related]
4. Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease.
Miyazaki I; Asanuma M
Curr Med Chem; 2016; 23(7):686-700. PubMed ID: 26795196
[TBL] [Abstract][Full Text] [Related]
5. Enteric glial cells: new players in Parkinson's disease?
Clairembault T; Leclair-Visonneau L; Neunlist M; Derkinderen P
Mov Disord; 2015 Apr; 30(4):494-8. PubMed ID: 25100667
[TBL] [Abstract][Full Text] [Related]
6. Effects of Enteric Environmental Modification by Coffee Components on Neurodegeneration in Rotenone-Treated Mice.
Miyazaki I; Isooka N; Wada K; Kikuoka R; Kitamura Y; Asanuma M
Cells; 2019 Mar; 8(3):. PubMed ID: 30866481
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
Miyazaki I; Asanuma M
Curr Pharm Des; 2017; 23(33):4936-4947. PubMed ID: 28699520
[TBL] [Abstract][Full Text] [Related]
8. The Gut and Nonmotor Symptoms in Parkinson's Disease.
Klingelhoefer L; Reichmann H
Int Rev Neurobiol; 2017; 134():787-809. PubMed ID: 28805583
[TBL] [Abstract][Full Text] [Related]
9. Play in advance against neurodegeneration: exploring enteric glial cells in gut-brain axis during neurodegenerative diseases.
Seguella L; Capuano R; Sarnelli G; Esposito G
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):555-564. PubMed ID: 31025582
[No Abstract] [Full Text] [Related]
10. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
11. Enteric GFAP expression and phosphorylation in Parkinson's disease.
Clairembault T; Kamphuis W; Leclair-Visonneau L; Rolli-Derkinderen M; Coron E; Neunlist M; Hol EM; Derkinderen P
J Neurochem; 2014 Sep; 130(6):805-15. PubMed ID: 24749759
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson's Disease.
Miyazaki I; Asanuma M
Antioxidants (Basel); 2023 Apr; 12(4):. PubMed ID: 37107269
[TBL] [Abstract][Full Text] [Related]
13. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
[TBL] [Abstract][Full Text] [Related]
14. The nature of catecholamine-containing neurons in the enteric nervous system in relationship with organogenesis, normal human anatomy and neurodegeneration.
Natale G; Ryskalin L; Busceti CL; Biagioni F; Fornai F
Arch Ital Biol; 2017 Sep; 155(3):118-130. PubMed ID: 29220864
[TBL] [Abstract][Full Text] [Related]
15. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology.
Manfredsson FP; Luk KC; Benskey MJ; Gezer A; Garcia J; Kuhn NC; Sandoval IM; Patterson JR; O'Mara A; Yonkers R; Kordower JH
Neurobiol Dis; 2018 Apr; 112():106-118. PubMed ID: 29341898
[TBL] [Abstract][Full Text] [Related]
16. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates.
Arotcarena ML; Dovero S; Prigent A; Bourdenx M; Camus S; Porras G; Thiolat ML; Tasselli M; Aubert P; Kruse N; Mollenhauer B; Trigo Damas I; Estrada C; Garcia-Carrillo N; Vaikath NN; El-Agnaf OMA; Herrero MT; Vila M; Obeso JA; Derkinderen P; Dehay B; Bezard E
Brain; 2020 May; 143(5):1462-1475. PubMed ID: 32380543
[TBL] [Abstract][Full Text] [Related]
17. Environmental neurotoxic pesticide exposure induces gut inflammation and enteric neuronal degeneration by impairing enteric glial mitochondrial function in pesticide models of Parkinson's disease: Potential relevance to gut-brain axis inflammation in Parkinson's disease pathogenesis.
Palanisamy BN; Sarkar S; Malovic E; Samidurai M; Charli A; Zenitsky G; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Int J Biochem Cell Biol; 2022 Jun; 147():106225. PubMed ID: 35550926
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Effects of VEGF in the Enteric Nervous System.
Hecking I; Stegemann LN; Theis V; Vorgerd M; Matschke V; Stahlke S; Theiss C
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743202
[TBL] [Abstract][Full Text] [Related]
19. Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease.
West CL; Mao YK; Delungahawatta T; Amin JY; Farhin S; McQuade RM; Diwakarla S; Pustovit R; Stanisz AM; Bienenstock J; Barbut D; Zasloff M; Furness JB; Kunze WA
J Parkinsons Dis; 2020; 10(4):1477-1491. PubMed ID: 32925094
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Connection Between the Gut Microbiome and Parkinson's Disease Symptom Progression and Pathology: Implications for Supplementary Treatment Options.
Chan DG; Ventura K; Villeneuve A; Du Bois P; Holahan MR
J Parkinsons Dis; 2022; 12(8):2339-2352. PubMed ID: 36278360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
